Medtronic raises 2027 earnings forecast after strong Q1, shares offer 22% upside potential.

Medtronic has outperformed the S&P 500 recently, driven by a strong first quarter in 2027 that led the company to raise its non-GAAP earnings per share guidance for the full fiscal year. The company maintains healthy financial metrics, including a solid interest coverage ratio and manageable net debt to EBITDA ratio. Despite this strong performance, Medtronic shares are still trading at a 15% discount to the updated fair value estimate, suggesting potential for a 22% price increase by October 2027 and over 11% annual total returns through fiscal year 2032. This outlook highlights Medtronic as a promising investment opportunity for dividend growth investors.

Medtronic shares offer a dividend yield of 3.14% and trade at USD 91.39 on Pluang as of Sep 22, 2026 21:31 WIB. Despite the recent strong performance noted in the article, Pluang data shows a slight 0.39% decline in the last day and a high sell order activity at 88%. This contrasts with the article's positive outlook, highlighting different market dynamics at this moment.